A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, antiviral activity, and pharmacokinetics
of ABI-H0731 in combination with entecavir (ETV) and with ETV plus pegylated-interferon alpha
(Peg-IFNα) in Chinese participants with chronic hepatitis B virus infection (cHBV)